Celyad Oncology S.A.
CYAD
Pozycja w akcjach
#31629
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to... Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
Cena akcji
$0.25502336
Ostatnia synchronizacja: 2026-10-16
Kapitalizacja rynkowa
$12.05M
Zmiana (1 dzień)
0.47%
Zmiana (1 rok)
-45.74%
Kraj
BE
Handel Celyad Oncology S.A. (CYAD)
Kategoria
Healthcare
Kapitalizacja rynkowa Celyad Oncology S.A.(CYAD)
Kapitalizacja rynkowa: $12.05M
Na dzień October 2026 spółka Celyad Oncology S.A. ma kapitalizację rynkową wynoszącą $12.05M. Według naszych danych, czyni to Celyad Oncology S.A. 31629th najcenniejszą firmą na świecie pod względem kapitalizacji rynkowej. Kapitalizacja rynkowa to całkowita wartość rynkowa wszystkich wyemitowanych akcji spółki giełdowej i jest powszechnie stosowana do oceny jej wartości.
Historia kapitalizacji rynkowej Celyad Oncology S.A. od 2015 do 2026
CYAD w porównaniu do 5 najpopularniejszych stocks
